BRPI0924207A2 - solvato dimetilsulfóxido cristalino do darunavir, composição farmacêutica, método de inibição da atividade protease de retrovírus, uso de solvato dimetilsulfóxido cristalino do darunavir, solvato tetraidrofurano cristalino do darunavir, forma amorfa do darunavir, uso de uma forma amorfa do darunavir - Google Patents

solvato dimetilsulfóxido cristalino do darunavir, composição farmacêutica, método de inibição da atividade protease de retrovírus, uso de solvato dimetilsulfóxido cristalino do darunavir, solvato tetraidrofurano cristalino do darunavir, forma amorfa do darunavir, uso de uma forma amorfa do darunavir

Info

Publication number: BRPI0924207A2
Authority: BR; Brazil
Prior art keywords: darunavir; crystalline; solvate; dimethyl sulfoxide; amorphous
Prior art date: 2009-01-29

Application number

BRPI0924207A

Other languages

English (en)

Inventor

Ehud Marom

Original Assignee

Mapi Pharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-29

Filing date

2009-12-08

Publication date

2016-07-26

2009-12-08 Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd

2016-07-26 Publication of BRPI0924207A2 publication Critical patent/BRPI0924207A2/pt

Links

CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 title 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 title 4
229960005107 darunavir Drugs 0.000 title 3
239000012453 solvate Substances 0.000 title 3
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 title 2
108091005804 Peptidases Proteins 0.000 title 1
239000004365 Protease Substances 0.000 title 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
230000000694 effects Effects 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 title 1
241001430294 unidentified retrovirus Species 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Virology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

BRPI0924207A 2009-01-29 2009-12-08 solvato dimetilsulfóxido cristalino do darunavir, composição farmacêutica, método de inibição da atividade protease de retrovírus, uso de solvato dimetilsulfóxido cristalino do darunavir, solvato tetraidrofurano cristalino do darunavir, forma amorfa do darunavir, uso de uma forma amorfa do darunavir BRPI0924207A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US14805509P	2009-01-29	2009-01-29
US24281809P	2009-09-16	2009-09-16
PCT/IL2009/001158 WO2010086844A1 (en)	2009-01-29	2009-12-08	Polymorphs of darunavir

Publications (1)

Publication Number	Publication Date
BRPI0924207A2 true BRPI0924207A2 (pt)	2016-07-26

Family

ID=42395158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0924207A BRPI0924207A2 (pt)	2009-01-29	2009-12-08	solvato dimetilsulfóxido cristalino do darunavir, composição farmacêutica, método de inibição da atividade protease de retrovírus, uso de solvato dimetilsulfóxido cristalino do darunavir, solvato tetraidrofurano cristalino do darunavir, forma amorfa do darunavir, uso de uma forma amorfa do darunavir

Country Status (11)

Country	Link
US (1)	US20120035142A1 (pt)
EP (2)	EP2381786B1 (pt)
CN (1)	CN102300465A (pt)
AU (1)	AU2009339140A1 (pt)
BR (1)	BRPI0924207A2 (pt)
CA (1)	CA2750774A1 (pt)
ES (1)	ES2532755T3 (pt)
IL (1)	IL246900A0 (pt)
MX (1)	MX2011007790A (pt)
PL (1)	PL2381786T3 (pt)
WO (1)	WO2010086844A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8921415B2 (en)	2009-01-29	2014-12-30	Mapi Pharma Ltd.	Polymorphs of darunavir
WO2011048604A2 (en)	2009-09-17	2011-04-28	Matrix Laboratories Limited	An improved process for the preparation of darunavir
ES2546866T3 (es)	2009-12-16	2015-09-29	Hetero Research Foundation	Polimorfos de darunavir
EP2528923B1 (en)	2010-01-28	2014-07-30	Mapi Pharma Limited	Process for the preparation of darunavir and darunavir intermediates
WO2011141921A1 (en) *	2010-05-10	2011-11-17	Hetero Research Foundation	Darunavir compositions
EP2571355B1 (en)	2010-05-20	2016-09-07	Hetero Research Foundation	Crystalline hydrochloride salt of darunavir
EP2632270A1 (en) *	2010-10-28	2013-09-04	Mapi Pharma Limited	Polymorphs of febuxostat
WO2012107889A1 (en)	2011-02-10	2012-08-16	Ranbaxy Laboratories Limited	Process for the preparation of amorphous darunavir
WO2013114382A1 (en)	2011-12-05	2013-08-08	Mylan Laboratories Ltd	Crystalline darunavir
WO2013108105A2 (en)	2012-01-18	2013-07-25	Aurobindo Pharma Limited	Novel solvates of darunavir
WO2013189049A1 (zh) *	2012-06-20	2013-12-27	上海迪赛诺药业有限公司	制备达芦那韦无定形物的方法
CN103509031B (zh) *	2012-06-20	2016-04-27	上海迪赛诺药业有限公司	制备达芦那韦无定形物的方法
ES2848216T3 (es) *	2012-07-24	2021-08-05	Laurus Labs Ltd	Un proceso para la preparación de Darunavir
CN105315178B (zh) *	2014-07-09	2018-07-06	浙江九洲药业股份有限公司	达芦那韦相关物质及其制备方法
CN106854212A (zh)	2015-12-08	2017-06-16	浙江九洲药业股份有限公司	一种达芦那韦无定型的制备方法
CN107235987A (zh) *	2016-03-28	2017-10-10	浙江九洲药业股份有限公司	一种地瑞那韦甲醇溶剂化物及其制备方法和用途
CN108727401A (zh) *	2017-04-20	2018-11-02	盐城迪赛诺制药有限公司	达鲁那韦新晶型及其制备方法和应用
CN109632555B (zh) *	2018-12-28	2021-07-27	上海新黄河制药有限公司	一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5968942A (en)	1992-08-25	1999-10-19	G. D. Searle & Co.	α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
AU7669794A (en)	1993-08-24	1995-03-21	G.D. Searle & Co.	Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
NZ508855A (en) *	1998-06-19	2003-10-31	Vertex Pharma	Sulfonamide inhibitors of HIV aspartyl protease
JP4776775B2 (ja)	1998-06-23	2011-09-21	アメリカ合衆国	Ｈｉｖ感染哺乳動物を治療するための医薬組成物
ES2503551T5 (es)	2002-05-16	2021-10-28	Janssen Sciences Ireland Unlimited Co	Formas pseudopolimórficas de un inhibidor de la proteasa de VIH
JP2008520672A (ja) *	2004-11-16	2008-06-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法
WO2011048604A2 (en) *	2009-09-17	2011-04-28	Matrix Laboratories Limited	An improved process for the preparation of darunavir

2009
- 2009-12-08 US US13/146,727 patent/US20120035142A1/en not_active Abandoned
- 2009-12-08 ES ES09839083.4T patent/ES2532755T3/es active Active
- 2009-12-08 AU AU2009339140A patent/AU2009339140A1/en not_active Abandoned
- 2009-12-08 CN CN2009801558012A patent/CN102300465A/zh active Pending
- 2009-12-08 CA CA2750774A patent/CA2750774A1/en not_active Abandoned
- 2009-12-08 BR BRPI0924207A patent/BRPI0924207A2/pt not_active IP Right Cessation
- 2009-12-08 PL PL09839083T patent/PL2381786T3/pl unknown
- 2009-12-08 EP EP09839083.4A patent/EP2381786B1/en not_active Not-in-force
- 2009-12-08 MX MX2011007790A patent/MX2011007790A/es not_active Application Discontinuation
- 2009-12-08 WO PCT/IL2009/001158 patent/WO2010086844A1/en not_active Ceased
- 2009-12-08 EP EP14187453.7A patent/EP2898776A1/en not_active Ceased
2016
- 2016-07-21 IL IL246900A patent/IL246900A0/en unknown

Also Published As

Publication number	Publication date
WO2010086844A1 (en)	2010-08-05
AU2009339140A1 (en)	2011-08-11
IL246900A0 (en)	2016-09-29
EP2381786A1 (en)	2011-11-02
ES2532755T3 (es)	2015-03-31
CA2750774A1 (en)	2010-08-05
MX2011007790A (es)	2011-11-18
CN102300465A (zh)	2011-12-28
US20120035142A1 (en)	2012-02-09
PL2381786T3 (pl)	2015-06-30
EP2381786A4 (en)	2012-06-20
EP2381786B1 (en)	2014-12-24
EP2898776A1 (en)	2015-07-29

Legal Events

Date	Code	Title	Description
2016-09-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A E 6A ANUIDADES.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2021-06-08	B350	Update of information on the portal [chapter 15.35 patent gazette]

Publication	Publication Date	Title
DK3097925T3 (da)	2019-08-05	Farmaceutisk sammensætning
BRPI1004940A2 (pt)	2018-06-19	composição farmacêutica
ES2769357T8 (es)	2020-08-06	Formas farmacéuticas de apixaban
BRPI1012539A2 (pt)	2016-03-29	composições farmacêuticas
SMT201700095B (is)	2017-03-08	Composizioni farmaceutiche per inalazione
LT3061445T (lt)	2023-09-25	Labai koncentruotos farmacinės kompozicijos
BR112012000769A2 (pt)	2016-02-23	lupeol -tipo de derivados triterpenos como antivirais
BRPI1014316A2 (pt)	2016-04-05	composição, e, uso de uma composição
BRPI1015939A2 (pt)	2016-09-27	composição farmacêutica
LT3403654T (lt)	2019-09-10	Geriamosios kortikosteroido kompozicijos
SMT201400069B (it)	2014-07-07	Formulazione farmaceutica
DK2391349T3 (da)	2014-11-03	Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
BR112012003842A2 (pt)	2016-03-22	composição farmacêutica, método de formulação e uso da mesma
BRPI1005931A8 (pt)	2017-12-26	associação de compostos, uso de uma associação, produto em forma de kit, uso de um produto e composição farmacêutica
DK2442799T3 (da)	2017-01-02	Fast farmaceutisk sammensætning omfattende rivaroxaban
IT1394400B1 (it)	2012-06-15	Composizioni farmaceutiche
EP2477628A4 (en)	2013-04-17	PREPARATION OF CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE
EP2443125A4 (en)	2012-12-12	Camptothecin derivatives
BR112012014028A2 (pt)	2017-12-12	uso de uma composição
DK2391351T3 (da)	2014-12-01	Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
BRPI1006953A2 (pt)	2016-04-26	composição farmacêutica, e, uso de uma composição
BR112012000831A2 (pt)	2019-09-24	compostos, composições farmacêuticas e métodos relacionados
EP2475251A4 (en)	2012-10-24	STABLE HYALURONANE / STEROID FORMULATION
EP2479211A4 (en)	2013-06-05	FLUOR RUBBER COMPOSITION
EP2413933A4 (en)	2012-09-19	COMPOSITION OF 2,4,6-TRIFLUOR-N- [6- (1-METHYL-PIPERIDIN-4-CARBONYL) -PYRIDIN-2-YL] -BENZAMIDE